Erratum
for
Bottomley et al., J Clin Oncol 27 (18) 2916-2923.
Journal of Clinical Oncology, Vol 27, No 27 (September 20), 2009: pp. 4630
© 2009 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2009.25.7469
ERRATA
The June 20, 2009, article by Bottomley et al, entitled, "Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group" (J Clin Oncol 27:2916–2923, 2009), contained an error.
In the Methods section of the Abstract, the induction and maintenance doses for PEG-IFN- -2b were given as 6 g/kg/wk and 3 g/kg/wk, respectively, whereas they should have been 6 µg/kg/wk and 3 µg/kg/wk, respectively, as follows:
"A total of 1,256 patients with stage III melanoma were randomly assigned after full lymphadenectomy to receive either observation (n = 629) or PEG-IFN- -2b (n = 627): induction 6 µg/kg/wk for 8 weeks then maintenance 3 µg/kg/wk for an intended total duration of 5 years."
The online version has been corrected in departure from the print.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
|
